Pralsetinib
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively[1].
Product Specifications
CAS Number
2097132-94-8
Product Name Alternative
BLU-667
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Blu667.html
Purity
99.98
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C([C@@]1(OC)CC[C@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C
Molecular Formula
C27H32FN9O2
Molecular Weight
533.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY403158 100 µg
Morg1 (WDR83) (NM_032332) Human Over-expression Lysate
Sign In for Pricing
View Details 
